Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FleuryBSP:FLRY3 -1.64%90 5-Year Yield-on-Cost % is 11.17 as of Jul. 14, 2026, which is 75% above its 10-year median of 6.40. GuruFocus rates BSP:FLRY3 with a GF Score™ of 90/100 and a GF Value™ of R$17.48 (Fairly Valued). The stock has 5 warning signs investors should review. Among 65 Medical Diagnostics & Research companies, Fleury ranks better than 87.69% on this metric.
Fleury's yield on cost for the quarter that ended in Mar. 2026 was 11.17.
The historical rank and industry rank for Fleury's 5-Year Yield-on-Cost % or its related term are showing as below:
BSP:FLRY3'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.74 Med: 6.4 Max: 17.13
Current: 11.17
During the past 13 years, Fleury's highest Yield on Cost was 17.13. The lowest was 0.74. And the median was 6.40.
BSP:FLRY3's 5-Year Yield-on-Cost % is ranked better than 87.69% of 65
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.42
vs BSP:FLRY3: 11.17
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Fleury 5-Year Yield-on-Cost % Related Terms
BSP:FLRY3 vs TMO, DHR, IDXX: 5-Year Yield-on-Cost % Comparison
For the Diagnostics & Research subindustry, Fleury's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fleury 5-Year Yield-on-Cost % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Fleury's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Fleury's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Fleury is calculated as
Fleury (BSP:FLRY3) has a 5-Year Yield-on-Cost % of 11.17 as of Jul. 14, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Fleury and its competitors. This is 75% above median its historical median of 6.40. Over the past decade, Fleury's 5-Year Yield-on-Cost % has ranged from 0.74 to 17.13. According to the industry distribution chart, Fleury ranks #8 out of 65 companies in the Medical Diagnostics & Research industry, placing it in the top 12.3%.
Is Fleury's 5-Year Yield-on-Cost % too high?
Fleury's current 5-Year Yield-on-Cost % of 11.17 is 75% above median its 10-year median of 6.40. Over the past 10 years, this metric has ranged from a low of 0.74 to a high of 17.13. The Medical Diagnostics & Research industry median 5-Year Yield-on-Cost % is 2.42. Fleury's value of 11.17 is 361.6% above this industry median. Based on the distribution chart, Fleury ranks #8 out of 65 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Fleury has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fleury's 5-Year Yield-on-Cost % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Fleury ranks #8 out of 65 companies for 5-Year Yield-on-Cost %. This places Fleury in the top 12% of its industry — outperforming the majority of peers. The industry median 5-Year Yield-on-Cost % is 2.42. Fleury's value of 11.17 is 361.6% above this benchmark. Historically, Fleury's own 5-Year Yield-on-Cost % has ranged from 0.74 to 17.13 over the past decade. While the company's 10-year median is 6.40 vs. the industry median of 2.42, Fleury has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Diagnostics & Research company?
The median 5-Year Yield-on-Cost % among Medical Diagnostics & Research companies is 2.42, based on 65 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fleury's current 5-Year Yield-on-Cost % of 11.17 is 361.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Fleury and its competitors. For the Medical Diagnostics & Research industry, the median 5-Year Yield-on-Cost % is 2.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fleury's current 5-Year Yield-on-Cost % is 11.17, which is 75% above median its own 10-year median of 6.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fleury stock overvalued right now?
Based on GuruFocus' analysis, Fleury (BSP:FLRY3) is currently considered Fairly Valued. The stock's GF Value™ is R$17.48, compared to a current price of R$16.15 — trading 7.6% below its estimated fair value. The current 5-Year Yield-on-Cost % is 11.17, which is 75% above median its 10-year median of 6.40 and 361.6% above the Medical Diagnostics & Research industry median of 2.42. Fleury's overall GF Score™ is 90/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Fleury (BSP:FLRY3), the current 5-Year Yield-on-Cost % is 11.17 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fleury (BSP:FLRY3) Overvalued in 2026?
Based on GuruFocus' analysis, Fleury stock appears to be undervalued.
The current stock price of R$16.15 is trading 7.6% below its estimated GF Value™ of R$17.48.
GuruFocus considers Fleury to be Fairly Valued.
Key valuation signals for BSP:FLRY3:
5-Year Yield-on-Cost %: 11.17 (75% above median its 10-year median of 6.40)
GF Value™: R$17.48 vs. price of R$16.15 (7.6% below fair value)
Industry Position: 361.6% above the Medical Diagnostics & Research median (#8 of 65)
No single metric tells the full story. See the BSP:FLRY3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fleury SA is engaged in the provision of medical services in the diagnostic, laboratory support (Lab-to-Lab), infusions, clinical analysis, health management, medical care, orthopedics and ophthalmology, fertility, infusion areas and toxicological exams, among others. The company offers diagnostic medicine through physical service units and mobile diagnostic services for consumers. It also provides diagnostic support services to laboratories and hospitals. In addition, the company operates clinics and services in areas such as infusion therapy, orthopedics, ophthalmology, reproductive medicine, and oncology. It has two reportable business segments: Diagnostic Medicine and Integrated Medicine. The maximum revenue is generated from the Diagnostic Medicine Segment.
90GF Score
Get the complete analysis for BSP:FLRY3
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:FLRY3 has been successfully added to your 
